Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections
Eligibility Criteria
Inclusion Criteria:
- 18~60 years old (including the critical value), male and female are not limited.
- Body mass index BMI [weight (kg)/height2 (m2)] is 18.0~28.0 (including the critical value), male weight should be ≥50kg, female weight should be ≥45kg.
- Diagnosed with HIV-1 infection.
- Those who did not plan to have children within 2 weeks prior to screening and within 3 months after the end of the trial and who agreed to use effective non-pharmacological contraception during the trial.
- Subjects should fully understand the purpose, nature and methods of the test and the possible adverse effects and voluntarily participate in this test.
Exclusion Criteria:
Subjects meeting any of the following criteria will not be allowed to enter the trial
- The presence of any of the following 1)Unexplained persistent irregular fever of 38°C or more for >1 month. 2)Diarrhea (stools more than 3 times/day), >1 month. 3)Weight loss of 10% or more within 6 months. 4)Recurrent oral fungal infections. 5)Recurrent herpes simplex virus infection or herpes zoster virus infection. 6)Pneumocystis carinii pneumonia (PCP). 7)Recurrent bacterial pneumonia. 8)Active tuberculosis or non-tuberculous mycobacteriosis. 9)Deep fungal infection. 10)Occupational lesions of the central nervous system. 11)Dementia in young and middle-aged adults. 12)Active cytomegalovirus (CMV) infection. 13)Toxoplasma encephalopathy. 14)Malnefield basket disease. 15)Recurrent sepsis. 16)Kaposi's sarcoma, lymphoma.
- Patients who have received antiviral therapy and/or HIV vaccination;
- HBsAg of (+), and/or anti-HCV of (+);
- Abnormal liver function (ALT/AST>3XULN, or TBIL>2XULN);
- Creatinine clearance<70mL/min (Equation of calculation: Cockcroft-Gault)
- Existing severe chronic disease, metabolic disease (such as diabetes), neurological and psychiatric disease;
- History of pancreatitis;
- Regnant, lactating women and women of childbearing age who cannot use contraception as required;
- People with allergies or known allergies to the ingredients of this medicine;
- People with a history of smoking within 12 months before screening (the average number of cigarettes smoked per day is 35.);
- People with a history of alcoholism within 12 months before screening(Drink N14 units of alcohol per week on average: 1 unit = 285mL of beer, or 25mL of spirits, or 150mL of wine) or positive alcohol breath test before enrollment;
- People with have a history of drug abuse within 12 months before screening or those who tested positive for addictive substances before enrollment;
- Participated in other drug trials within 3 months before screening;
- The investigator believes that the subject has other conditions that are not suitable for participating in the trial.
Sites / Locations
- Beijing You'an Hospital, Beijing Medical University
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Dose 5 mg
Dose 20 mg
Dose 40 mg
Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.
Injected subcutaneously at room temperature into the abdomen (moles, scar tissue, bruises or areas other than the navel) and administered once a week for 4 weeks, with no more than 2.0 mL volume administered to a single site.